Wealth Enhancement Trust Services’s Ironwood Pharmaceuticals IRWD Stock Holding History

Wealth Enhancement Trust Services’s Portfolio IRWD Stock Details IRWD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$501	Buy	+119	New	+$459	﹤0.01%	1243

Other funds holding IRWD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

HIM

Hillsdale Investment Management Toronto, Ontario, Canada $4.39B AUM 72.96% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.43B AUM 49.04% 1-Year Est. Return

Wealth Enhancement Trust Services's IRWD Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Ironwood Pharmaceuticals (IRWD) in Q2 2026: 119 shares worth $501. The stake represents ﹤0.01% of the portfolio and ranks #1243 among its holdings.

125 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.

Wealth Enhancement Trust Services held 119 shares of Ironwood Pharmaceuticals worth $501 as of Q2 2026.
Ironwood Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Ironwood Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1243 holding.
125 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.